Long-Term Effects of Laparoscopic Roux-en-Y Gastric Bypass on Diabetes Mellitus, Hypertension and Dyslipidaemia in Morbidly Obese Patients

被引:31
作者
Dogan, K. [1 ]
Betzel, B. [1 ]
Homan, J. [1 ]
Aarts, E. O. [1 ]
Ploeger, N. [1 ]
de Boer, H. [2 ]
Aufenacker, Th. J. [1 ]
van Laarhoven, C. J. H. M. [3 ]
Janssen, I. M. C. [1 ]
Berends, F. J. [1 ]
机构
[1] Rijnstate Hosp, Dept Surg, NL-6800 TA Arnhem, Netherlands
[2] Rijnstate Hosp, NL-6800 TA Arnhem, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Surg, NL-6525 ED Nijmegen, Netherlands
关键词
Morbid obesity; Bariatric surgery; Roux-en-Y gastric bypass; Diabetes mellitus type 2; Hypertension; Dyslipidaemia; BARIATRIC SURGERY; MEDICAL THERAPY; RISK-FACTORS; WEIGHT; REMISSION; MORTALITY; GLUCOSE;
D O I
10.1007/s11695-014-1310-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
Severely obese patients have an increased risk for developing metabolic complications such as type 2 diabetes mellitus (T2DM), dyslipidaemia (DL) and hypertension (HT). The aim of the present study is to research the effect of a primary laparoscopic Roux-en-Y gastric bypass (LRYGB) on T2DM, HT and DL in the long-term. Fifty-two out of 89 (58 %) adult severely obese patients with T2DM who had received a LRYGB between January 2000 and December 2008 were evaluated. Primary outcome of evaluation was remission of T2DM according to the definition of 2009 consensus statement. Complete remission was defined as achievement fasting plasma glucose (FPG) of < 5.6 mmol/l (< 100.8 mg/dL) and HbA1c < 42 mmol/mol (< 6.0 %)) without glucose-lowering medication for at least 1 year. Partial remission was defined as a FPG of 5.6-6.9 mmol/l (100.8-124.2 mg/dL) and HbA1c 42-48 mmol/mol (6.0-6.5 %), without glucose-lowering medication for at least 1 year. Remission of T2DM was considered if the patient met the criteria for complete or partial remission. Secondary outcomes were remission of HT, DL and changes in medication use. Patients had a mean age of 47.5 +/- 9.6 years, body mass index of 46.6 +/- 6.4 kg/m(2) and a mean duration of T2DM of 6.1 +/- 5.4 years at the time of surgery. The mean post-operative follow-up period was 6.9 +/- 2.3 years. At the end of the follow-up, mean weight loss was 60 +/- 24 % excess weight loss (EWL) and 26 +/- 10 % total body weight loss (TBWL). Mean HbA1c level had significantly decreased from 64.8 +/- 19.7 mmol/mol to 46.4 +/- 12.9 mmol/l (p < 0.0001). Overall medication use was reduced from 85 % to 37 % of the patients (p < 0.0001), while the number of insulin users was reduced from 40 % to 6 % (p < 0.0001). Nineteen percent of the patients had a relapse of T2DM during follow-up. Pre-operative HbA1ac level (odds ratio 0.911, p = 0.020) and duration of T2DM (odds ratio 0.637, p = 0.010) were independent risk factors for failed remission of T2DM. The number of patients with HT was significantly reduced from 73 % to 54 % (p = 0.042), and number of patients with DL was non-significantly decreased from 71 % to 54 % (p = 0.068). The laparoscopic RYGB operation results in a sustained EWL of 60 % (26 % TBWL) with 52 % long-term remission of T2DM. However, 19 % of the patients had a relapse of their T2DM. Furthermore, HT and DL improved markedly.
引用
收藏
页码:1835 / 1842
页数:8
相关论文
共 44 条
[1]   Preoperative Fasting Plasma C-Peptide Level May Help to Predict Diabetes Outcome After Gastric Bypass Surgery [J].
Aarts, E. O. ;
Janssen, J. ;
Janssen, I. M. C. ;
Berends, F. J. ;
Telting, D. ;
de Boer, H. .
OBESITY SURGERY, 2013, 23 (07) :867-873
[2]   Prevalence of Anemia and Related Deficiencies in the First Year following Laparoscopic Gastric Bypass for Morbid Obesity [J].
Aarts, E. O. ;
van Wageningen, B. ;
Janssen, I. M. C. ;
Berends, F. J. .
JOURNAL OF OBESITY, 2012, 2012
[3]   Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes [J].
Abbatini, F. ;
Rizzello, M. ;
Casella, G. ;
Alessandri, G. ;
Capoccia, D. ;
Leonetti, F. ;
Basso, N. .
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2010, 24 (05) :1005-1010
[4]   Health Benefits of Gastric Bypass Surgery After 6 Years [J].
Adams, Ted D. ;
Davidson, Lance E. ;
Litwin, Sheldon E. ;
Kolotkin, Ronette L. ;
LaMonte, Michael J. ;
Pendleton, Robert C. ;
Strong, Michael B. ;
Vinik, Russell ;
Wanner, Nathan A. ;
Hopkins, Paul N. ;
Gress, Richard E. ;
Walker, James M. ;
Cloward, Tom V. ;
Nuttall, R. Tom ;
Hammoud, Ahmad ;
Greenwood, Jessica L. J. ;
Crosby, Ross D. ;
McKinlay, Rodrick ;
Simper, Steven C. ;
Smith, Sherman C. ;
Hunt, Steven C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (11) :1122-1131
[5]  
[Anonymous], GUID ATC CLASS DDD A
[6]   Bariatric surgery: A systematic review and meta-analysis [J].
Buchwald, H ;
Avidor, Y ;
Braunwald, E ;
Jensen, MD ;
Pories, W ;
Fahrbach, K ;
Schoelles, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (14) :1724-1737
[7]   Metabolic/Bariatric Surgery Worldwide 2011 [J].
Buchwald, Henry ;
Oien, Danette M. .
OBESITY SURGERY, 2013, 23 (04) :427-436
[8]   Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis [J].
Buchwald, Henry ;
Estok, Rhonda ;
Fahrbach, Kyle ;
Banel, Deirdre ;
Jensen, Michael D. ;
Pories, Walter J. ;
Bantle, John P. ;
Sledge, Isabella .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (03) :248-U81
[9]   How Do We Define Cure of Diabetes? [J].
Buse, John B. ;
Caprio, Sonia ;
Cefalu, William T. ;
Ceriello, Antonio ;
Del Prato, Stefano ;
Inzucchi, Silvio E. ;
McLaughlin, Sue ;
Phillips, Gordon L., II ;
Robertson, R. Paul ;
Rubino, Francesco ;
Kahn, Richard ;
Kirkman, M. Sue .
DIABETES CARE, 2009, 32 (11) :2133-2135
[10]   Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass [J].
Chikunguwo, Silas M. ;
Wolfe, Luke G. ;
Dodson, Patricia ;
Meador, Jill G. ;
Baugh, Nancy ;
Clore, John N. ;
Kellum, John M. ;
Maher, James W. .
SURGERY FOR OBESITY AND RELATED DISEASES, 2010, 6 (03) :254-259